Navigation Links
Cervical Cancer Vaccine Approved for Use

Medicines Safety Authority Medsafe has approved the use of Gardasil, cervical cancer vaccine on Thursday. Several health professionals are calling for its use in a national// immunization program.

The vaccine is said to offer immunity against four strains of Human Papilloma Virus (HPV) which is a common sexually transmitted infection. Although HPV infects about half of sexually active adults sometime during their life, it is usually harmless. However, it can cause the development of abnormal cells in the cervix lining, which can turn cancerous.

Presently Gardasil is recommended for use from ages 9 to 26, before women become sexually active and is expected to eventually included in the national immunization schedule.

Still Medsafe says women will need to have regular pap smears because of limited protection, besides which it is not known how long the vaccine will last.

According to Biopharmaceutical company CSI Limited Gardasil will be available in New Zealand in September.

The vaccine will have to be included in the Ministry of Health's national immunization program before its nationwide implementation. However the next review of its schedule isn't due until 2008.

Dr Dynes McConnell, from the Royal Australasian College of Obstetricians and Gynaecologists has warned for the need for action before then. She says that New Zealand will face a risk of falling behind if the vaccine is not introduced on a national level within the next one to three years.

Each year around 180 women are diagnosed with cervical cancer in New Zealand and around 60 die from the disease.


'"/>




Page: 1

Related medicine news :

1. Virus Level could Predict Cervical Cancer Risk
2. Smallpox Vaccine May Help Fight Cervical Cancer
3. Obesity Increases Risk of Cervical Cancer
4. Reducing The Risk Of Cervical Cancer
5. Improving Fertility In Patients With Cervical Cancer
6. Vaccine for Cervical cancer
7. Cervical spinal injury patients may have more damage left undetected
8. Cervical Cancer Vaccine To Be Developed In India
9. Cervical Cancer Can Now Be Better Handled With Gene Silencing Therapy
10. Cervical Cancer Recurrence Risk Even After Removal Of Pre-Cancerous Cells
11. HPV Vaccines for Cervical Cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/8/2016)... ... December 08, 2016 , ... Coffey Agencies, a ... and commercial clients in the northern Alabama and Georgia regions, is embarking on ... 1977, Nobis Works has built a network of support and education facilities to ...
(Date:12/7/2016)... , ... December 07, 2016 , ... DrugDev ... announcement that it is one of the early adopters completing EU-U.S. Privacy Shield Certification ... designed to provide companies on both sides of the Atlantic with a mechanism to ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... ... celebrating the passage of the most comprehensive mental health systems reform legislation in ... support of the President, and the commitment of our elected officials to improving ...
(Date:12/7/2016)... York, NY (PRWEB) , ... December 07, 2016 ... ... amounts of the drug in their bodies, a researcher at the Icahn School ... journal Pediatric Research. , The study found that when young children are exposed ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... of Smart Device Remote Control through a new partnership with Splashtop Inc. This ... strengthens its mobile solutions to help businesses maximize their uptime and productivity. , ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016 Henry Schein, Inc. (Nasdaq: ... care products and services to office-based dental, animal health and ... equity investment in Marrodent, one of Poland,s ... $32 million. This transaction was announced on August 30, 2016. ... Poland since 2014, and Marrodent marks ...
(Date:12/8/2016)... Dec 8, 2016 Research and Markets has announced ... report to their offering. ... , The report provides separate comprehensive ... , and Rest of World. Annual estimates and ... historic analysis is provided for these markets. Market data and analytics are ...
(Date:12/7/2016)... Dec. 7, 2016 "Lantus (Insulin Glargine) Biosimilar Clinical Trial & ... biosimilar version of Lantus drug in clinical pipeline. Currently 5 biosimilar version ... Japan , Kenya , Czech ... , China , Slovakia , ... 2 diabetes mellitus. The patent on Lantus expired in 2014. Lantus ...
Breaking Medicine Technology: